Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
Geron received $250 million in gross proceeds at closing, with access to an additional $125 million in debt Strengthens balance sheet to support the commercial launch of RYTELO™ in the U.S. and potential launch in…